Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P41181 (
collecting duct
)
5,183
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Urodilatin (URO) [ANP-(95-126)] is an analogue of
atrial natriuretic peptide
(alpha-ANP) [ANP-(99-126)] that was first isolated from human urine. In rat mesangial cells, URO competed with high affinity for non-guanylate cyclase-coupled ANPR-C receptors [concentration at which 50% labeled ligand is displaced (IC50) approximately 70 pM], but with lesser affinity to the guanylate cyclase-linked ANPR-A receptors (IC50 approximately 800 pM). alpha-ANP bound to both receptors with similar affinity [dissociation constant (Kd) approximately 150 pM]. In papillary
collecting duct
homogenates, which possess only ANPR-A receptors, the apparent Kd value averaged 229 pM for alpha-ANP and 2.7 nM for URO. Intravenous URO was at least as potent and effective as alpha-ANP in inducing diuresis and natriuresis in anesthetized rats, but URO was approximately 10-fold less potent in stimulating guanosine 3',5'-cyclic monophosphate generation in mesangial and inner medullary
collecting duct
cells. We conclude that URO has a lesser affinity than alpha-ANP for guanylate cyclase-coupled ANP receptors in the kidney and that the relative natriuretic potency of URO in vivo cannot be directly attributed to its binding characteristics with ANPR-A receptors.
...
PMID:Urodilatin: binding properties and stimulation of cGMP generation in rat kidney cells. 809 70
The terminal inner medullary
collecting duct
(IMCD) plays an important role in determining the final urinary composition. Currently, there is no continuous cell line derived from this nephron segment. We have developed a cell line derived from the terminal IMCD of mice transgenic for the early region of simian virus SV40 (large T antigen). This cell line, mIMCD-3, retains many differentiated characteristics of this nephron segment including high transepithelial resistance (1,368 +/- 172 omega.cm2), inhibition of apical-to-basal sodium flux by amiloride (41 +/- 7%) and by
atrial natriuretic peptide
(
ANP
) (40 +/- 9%), the presence of the amiloride-sensitive sodium channel as determined by Western blot analysis, and accumulation of the major organic osmolytes in response to hypertonic stress. Significantly, mIMCD-3 cells adapted readily and were able to grow in hypertonic medium supplemented with NaCl and urea up to 910 mosmol/kgH2O. These extreme osmotic conditions exist in the renal medulla in vivo but are known to be lethal to most other cells. This cell line should be highly useful for the study of the cellular adaptation to osmotic stress and the cell biology and transport physiology of this nephron segment.
...
PMID:An osmotically tolerant inner medullary collecting duct cell line from an SV40 transgenic mouse. 821 1
The nature of sodium retention in cirrhosis complicated by ascites has been studied for the last 30 years. Resistance to the natriuretic action of
atrial natriuretic peptide
(
ANP
) may play a potential role in this sodium retention. To further evaluate this possibility, we studied 12 patients with biopsy-proven cirrhosis and ascites on 2 consecutive days after a 7-day period off diuretics while receiving a 20 mmol/day sodium restricted diet. Following a crossover design, patients underwent head-out water immersion (HWI) for 3 h and were infused with a alpha-human
ANP
for 2 h on 2 consecutive days. Blood and urine samples were collected hourly. Five patients displayed a natriuretic response to HWI, sufficient to achieve negative sodium balance, and these patients were termed responders. Each of these five patients also displayed a natriuretic response to
ANP
infusion. In contrast, the other seven patients (nonresponders) consistently failed to develop a natriuretic response to either maneuver. The two groups had similar elevations in plasma
ANP
concentrations, but at baseline differed in terms of plasma sodium, plasma renin activity, and serum aldosterone. Despite higher serum aldosterone concentrations, nonresponders excreted less potassium than responders during the peak effect of the interventions, suggesting greater sodium delivery to the aldosterone-sensitive nephron segment in responders. We conclude that the inability to mount an adequate sodium excretory response to HWI in patients with cirrhosis may be conveyed through increased antinatriuretic factors that decrease the sodium delivery to the medullary
collecting duct
and inhibit the natriuretic effect of
ANP
at that site.
...
PMID:Assessment of atrial natriuretic peptide resistance in cirrhosis with head-out water immersion and atrial natriuretic peptide infusion. 831 39
The inner medullary
collecting duct
(IMCD) is the final arbiter of renal Na+ excretion, and Na+ transport in this segment is controlled by a wide variety of hormones and renal autacoids. This review examines the mechanisms of IMCD Na+ transport and its regulation using results obtained from micropuncture and microcatheterization studies in the intact animal, as well as data from isolated perfused tubules, freshly prepared cell suspensions, and cultured IMCD cells. Where appropriate, results from closely related tissues such as the cortical
collecting duct
and model urinary epithelia are examined. Na+ reabsorption in this segment occurs predominantly via apical amiloride-sensitive Na+ channels and basolateral Na(+)-K(+)-adenosinetriphosphatase (Na(+)-K(+)-ATPase). Although there is some evidence for the activities of other transporters such as Na(+)-K(+)-2Cl- and Na-Cl cotransporters and Na+/H+ exchanger, their role in Na+ homeostasis remains undefined. Mineralocorticoids augment the activities of both apical Na+ channels and basolateral Na(+)-K(+)-ATPase by a variety of complex mechanisms. Prostaglandin E2 inhibits Na(+)-K(+)-ATPase and appears to mediate the actions of several peptide hormones, including endothelin, interleukin-1, and
atrial natriuretic peptide
[ANP-(31-67)]. Several peptides in the ANP family [ANP-(99-126), urodilatin, and brain natriuretic peptide] bind to guanylate cyclase-linked receptors, leading to inhibition of apical Na+ channel function. These mechanisms of regulation of IMCD Na+ transport likely play important roles in total body Na+ balance in health and disease.
...
PMID:Hormonal regulation of inner medullary collecting duct sodium transport. 836 30
Urodilatin is a recently described member of the
atrial natriuretic peptide
family, thought possibly to be synthesized in the kidney. To determine if urodilatin binding sites are present in rat and human kidney, we evaluated the effect of urodilatin on iodine-125-labeled
atrial natriuretic peptide
(
ANP
) (100 pM) binding to tissue sections using an in situ autoradiographic technique. 125I-
ANP
binding occurred primarily in glomeruli and medullary structures of both rat and human kidney. Increasing concentrations of urodilatin yielded a monophasic displacement of 125I-
ANP
binding with an IC50 of 4.2 nM, a value nearly identical to that achieved with unlabeled
ANP
(7.2 nM). In additional experiments, rat glomeruli and inner medullary
collecting duct
cells were isolated and incubated in vitro with either
ANP
or urodilatin (10(-11) to 10(-6) M) and cyclic guanosine-3',5'-monophosphate accumulation measured by radioimmunoassay. Dose-response curves for the two peptides were superimposable in each tissue; at 10(-6) M,
ANP
generated 613 +/- 41 and urodilatin 603 +/- 55 fmol cyclic guanosine monophosphate per 10 minutes per milligram protein in inner medullary
collecting duct
cells (p = NS). Thus, urodilatin is as effective as
ANP
in displacing 125I-
ANP
binding to both rat and human renal tissue and in generating cyclic guanosine monophosphate in renal target cells in the rat, suggesting that its physiological effects may occur through the same receptors and signaling pathways that mediate the actions of
ANP
.
...
PMID:Urodilatin binds to and activates renal receptors for atrial natriuretic peptide. 838
We studied the natriuretic effects of a combined mannitol and
atrial natriuretic peptide
(
ANP
) infusion in chronic caval dogs (TIVC) either responsive or unresponsive to an initial
ANP
infusion (75 ng.kg-1.min-1). The increment in urinary Na+ excretion (delta UNaV) to the initial
ANP
infusion in 11 TIVC responders was 127 and 1 mu eq/min in 7 nonresponders. A modest mannitol dose was then infused so as to augment distal Na+ delivery to the distal nephron but not flood the terminal inner medullary
collecting duct
(IMCD) with enormous quantities of salt and water. After mannitol, UNaV was 26 +/- 8 mu eq/min in TIVC responders and 24 +/- 4 mu eq/min in nonresponders. In these two groups of dogs, delta UNaV after manitol was 13 and 10 mu eq/min, respectively, from the previous experimental phase. During this stable mannitol-induced modest natriuresis,
ANP
was reinfused at initial dose levels. In TIVC responders, delta UNaV was 186 mu eq/min, a value greater than that obtained initially (P < 0.05), and delta UNaV in nonresponders was now 52 mu eq/min (P < 0.05). Because control and postmanitol UNaV was equivalent for each group, in the face of similar levels of glomerular filtration rate, blood pressure, and renal perfusion, it is difficult to conclude that only augmented delivery of Na+ to the IMCD converted TIVC nonresponders into responding dogs after mannitol and
ANP
. Other modulating factors may be involved.
...
PMID:Urinary sodium excretion in chronic caval dogs after combined infusions of mannitol and ANP. 844 33
Experimental nephrotic syndrome is characterized by abnormal sodium metabolism, reflected in a blunted natriuretic response both to volume expansion and to infused
atrial natriuretic peptide
(
ANP
). The studies presented here examined the relationships among plasma
ANP
concentration and urinary sodium (VNaV) and cyclic GMP excretion (UcGMPV) in vivo, and the responsiveness of isolated glomeruil and inner medullary
collecting duct
(IMCD) cells to
ANP
and urodilatin (renal natriuretic peptide; RNP) in vitro in rats with Heymann nephritis, an immunologically mediated model of nephrotic syndrome. Nine to 14 days after Ip injection of anti-Fx1A antiserum, rats were proteinuric and had a blunted natriuretic response to intravenous infusion of isotonic saline (2% body weight, given over 5 min). Thirty min after the onset of the infusion, plasma
ANP
concentration was increased to the same extent in both normal and nephritic rats, compared with their respective hydropenic controls. Despite this increase, UcGMPV was significantly less in nephritic rats after the saline infusion. Accumulation of cGMP by isolated glomeruil and IMCD cells from nephritic rats after incubation with
ANP
and RNP was also significantly reduced, compared with normal rats. This difference was not related to differences in either density or affinity of renal
ANP
receptors, but was abolished when accumulation of cGMP was measured in the presence of 10(-3) M isobutylmethylxanthine or Zaprinast, two different inhibitors of cyclic nucleotide phosphodiesterases (PDE). Infusion of Zaprinast into one renal artery in nephritic rats normalized both the natriuretic response to volume expansion and the increase in UcGMPV from the infused, but not the contralateral, kidney. Furthermore, cGMP-PDE activity was increased in IMCD cell homogenates from nephritic compared with normal rats (388 +/- 32 versus 198 +/- 93 pmol/min per mg protein, P < 0.03). These results indicate that blunted volume expansion natriuresis accompanied by cellular resistance to
ANP
in vitro occurs in an immunologic model of renal injury. The resistance is not related to an alteration in
ANP
release or binding to its renal receptors, but is suppressed by PDE inhibitors and is associated with increased renal cGMP. PDE activity, thus suggesting that enhanced cGMP-PDE activity may account for resistance to the natriuretic actions of
ANP
observed in vivo. This defect may represent the intrinsic sodium transport abnormality linked to sodium retention in nephrotic syndrome.
...
PMID:Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis. 872 92
Resistance to the natriuretic action of
atrial natriuretic peptide
(
ANP
) is a hallmark of states of pathological sodium retention including congestive heart failure, cirrhosis of the liver, and nephrotic syndrome. A variety of mechanisms including reduced delivery of filtrate to
ANP
-sensitive sites in the inner medullary
collecting duct
and diminished receptor density in this tubular segment have been offered to account for this resistance. Recent studies in experimental nephrotic syndrome and in liver disease produced by ligation of the common bile duct in rats suggest that increased activity of cyclic guanosine 3',5'-monophosphate (cGMP) phosphodiesterase may be an important mediator of renal resistance to
ANP
. Such increased enzyme activity rapidly catabolizes the second messenger cGMP, normally formed when
ANP
interacts with its biologically active natriuretic peptide. A receptors, thereby leading to blunted
ANP
responsiveness. This increased phosphodiesterase activity offers a novel approach to the management of clinical conditions associated with sodium retention and edema formation.
...
PMID:Phosphodiesterases (PDEs) hydrolyze the 3' phosphoester bond of the purine 3',5'-cyclic monophosphates, cAMP and cGMP. 876 Feb 35
Resistance to the natriuretic action of
atrial natriuretic peptide
(
ANP
) is a hallmark of states of pathological sodium retention including congestive heart failure, cirrhosis of the liver, and nephrotic syndrome. A variety of mechanisms including reduced delivery of filtrate to
ANP
-sensitive sites in the inner medullary
collecting duct
and diminished receptor density in this tubular segment have been offered to account for this resistance. Recent studies in experimental nephrotic syndrome and in liver disease produced by ligation of the common bile duct in rats suggest that increased activity of cyclic guanosine 3',5'-monophosphate (cGMP) phosphodiesterase may be an important mediator of renal resistance to
ANP
. Such increased enzyme activity rapidly catabolizes the second messenger cGMP, normally formed when
ANP
interacts with its biologically active natriuretic peptide A receptors, thereby leading to blunted
ANP
responsiveness. This increased phosphodiesterase activity offers a novel approach to the management of clinical conditions associated with sodium retention and edema formation.
...
PMID:Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. 876 Feb 36
Blunted volume expansion (VE) natriuresis and renal resistance to
atrial natriuretic peptide
(
ANP
) characterize states of pathological sodium retention. This study examined rats 1 to 3 wk after common bile-duct ligation (CBDL), at which time they had hyperbilirubinemia and hypoalbuminemia. Sham-operated normal rats (Sham) showed an increased sodium excretion rate (UNaV) from 1.0 +/- 0.1 to 16.3 +/- 3.9 muEq/min in response to acute VE (iv saline, 2 mL/100 g body wt over 5 min), whereas CBDL rats had a blunted response that was apparent after 1 wk and became maximal at 2 and 3 wk (0.3 +/- 0.1 to 3.2 +/- 0.4 muEq/min at 3 wk, P < 0.01 versus Sham response). The peak urinary cGMP excretion rate (UcGMPV) was also blunted (37.9 +/- 3.6 versus 87.5 +/- 8.3 pmol/min, P < 0.01) despite an even greater increase in plasma
ANP
concentration (Sham, 9.6 +/- 0.4 pg/mL in hydropenia to 22.8 +/- 2.6 pg/mL after VE; CBDL, 15.3 +/- 2.3 to 41.8 +/- 6.8 pg/mL).
ANP
-dependent cGMP accumulation by isolated inner medullary
collecting duct
(IMCD) cells from both Sham and CBDL rat kidneys was dose-dependent; however, at higher concentrations of
ANP
(> 10(-8) M), accumulation by cells from CBDL rats was significantly blunted, indicating resistance to
ANP
. Binding of 125I-
ANP
to IMCD cells was not different in CBDL rats compared with Sham control rats. Renal denervation improved but did not completely reverse the blunted natriuresis, and
ANP
resistance persisted in IMCD cells from denervated kidneys of CBDL rats. Incubation of IMCD cells with the phosphodiesterase inhibitors isomethylbutylxanthine or Zaprinast (each at 10(-3) M) restored
ANP
responsiveness in both innervated and denervated kidneys from CBDL rats, and intrarenal infusion of Zaprinast (10 micrograms/min) corrected the blunted increase in UNaV and UcGMPV after VE in rats with CBDL. These results suggest that
ANP
resistance in a model of abnormal sodium metabolism devoid of intrinsic renal disease may be related to increased activity of phosphodiesterase in renal target cells for
ANP
as well as to heightened renal nerve activity.
...
PMID:Mechanisms contributing to renal resistance to atrial natriuretic peptide in rats with common bile-duct ligation. 891 70
<< Previous
1
2
3
4
5
6
7
Next >>